| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... N engl j Med 369, 111-121, 2013 | 1441* | 2013 |
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Experts in Chronic Myeloid Leukemia Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013 | 622 | 2013 |
| European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ... Leukemia 30 (8), 1648-1671, 2016 | 445 | 2016 |
| Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial … F Lo-Coco, G Avvisati, M Vignetti, M Breccia, E Gallo, A Rambaldi, ... Blood, The Journal of the American Society of Hematology 116 (17), 3171-3179, 2010 | 345 | 2010 |
| Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the … U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ... Journal of Clinical Oncology 35 (6), 605-612, 2017 | 330 | 2017 |
| Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia F Lo-Coco, G Cimino, M Breccia, NI Noguera, D Diverio, E Finolezzi, ... Blood 104 (7), 1995-1999, 2004 | 292 | 2004 |
| Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ... Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009 | 287 | 2009 |
| Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population F Efficace, M Baccarani, M Breccia, G Alimena, G Rosti, F Cottone, ... Blood, The Journal of the American Society of Hematology 118 (17), 4554-4560, 2011 | 274 | 2011 |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ... New England Journal of Medicine, 2019 | 246 | 2019 |
| Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian … NI Noguera, M Breccia, M Divona, D Diverio, V Costa, S De Santis, ... Leukemia 16 (11), 2185-2189, 2002 | 232 | 2002 |
| Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution M Breccia, F Mandelli, MC Petti, M D’Andrea, E Pescarmona, SA Pileri, ... Leukemia research 28 (11), 1165-1169, 2004 | 162 | 2004 |
| Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic … MT Voso, S Fenu, R Latagliata, F Buccisano, A Piciocchi, MA Aloe-Spiriti, ... J Clin Oncol 31 (21), 2671-2677, 2013 | 153 | 2013 |
| Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib F Efficace, M Baccarani, M Breccia, F Cottone, G Alimena, GL Deliliers, ... Leukemia 27 (7), 1511-1519, 2013 | 146 | 2013 |
| Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem R Latagliata, MC Petti, S Fenu, M Mancini, MAA Spiriti, M Breccia, ... Blood, The Journal of the American Society of Hematology 99 (3), 822-824, 2002 | 144 | 2002 |
| Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. M Breccia, M Muscaritoli, Z Aversa, F Mandelli, G Alimena Journal of clinical oncology: official journal of the American Society of …, 2004 | 134 | 2004 |
| Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients I Iacobucci, G Saglio, G Rosti, N Testoni, F Pane, M Amabile, A Poerio, ... Clinical Cancer Research 12 (10), 3037-3042, 2006 | 122 | 2006 |
| Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study F Efficace, M Baccarani, G Rosti, F Cottone, F Castagnetti, M Breccia, ... British journal of cancer 107 (6), 904-909, 2012 | 121 | 2012 |
| Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up F Palandri, F Castagnetti, N Testoni, S Luatti, G Marzocchi, S Bassi, ... Haematologica 93 (12), 1792-1796, 2008 | 121 | 2008 |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party G Gugliotta, F Castagnetti, F Palandri, M Breccia, T Intermesoli, A Capucci, ... Blood, The Journal of the American Society of Hematology 117 (21), 5591-5599, 2011 | 119 | 2011 |
| Identification of risk factors in atypical chronic myeloid leukemia M Breccia, F Biondo, R Latagliata, I Carmosino, F Mandelli, G Alimena Haematologica 91 (11), 1566-1568, 2006 | 117 | 2006 |
